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Abstract
Melatonin is an endogenous hormone derived from tryptophan that is mainly released 
from the pineal gland in the dark. Melatonin regulates many biological functions such as 
sleep, circadian rhythm, immunity, and reproduction. Melatonin has a free radical scaven-
ger, anti-inflammatory, and antioxidant effects. It scavenges reactive oxygen and nitrogen 
species and increases antioxidant defenses, thus it prevents tissue damage and blocks 
transcriptional factors of pro-inflammatory cytokines. Due to its small size and amphiphi-
lic nature, it increases the efficacy of mitochondrial electron transport chain and reduces 
electron leakage. Melatonin prevents degenerative changes in the central nervous system 
in models of Alzheimer’s and Parkinson’s disease and reduces free radical damage to DNA 
which may lead to cancer and many other situations. Consequently, melatonin has benefi-
cial effects including stimulation of antioxidant enzymes, inhibition of lipid peroxidation, 
and so it contributes to protection from oxidative damages.
Keywords: melatonin, antioxidant, free radical, oxidative stress, anti-inflammatory, 
neurohormone, tryptophan, disease
1. Introduction
Melatonin, N-acetyl-5-methoxytryptamine, which was first isolated from bovine pineal glands 
[1], is an endogenous neurohormone derived from tryptophan [2]. Melatonin controls various 
physiologic processes, including circadian rhythms, mood regulation, anxiety, sleep, appetite, 
immune responses, and cardiac functions [3]. The sleep–wake cycle is the most overt circadian 
rhythm [4]. More or less sleep shows negative effects on biological and physiological processes 
including alterations in metabolic, endocrine, and immune pathways that lead to health problems 
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involving obesity, diabetes, hypertension, and respiratory diseases [4–6]. Timing of melatonin 
secretion is closely associated with the timing of sleep propensity, and it also coincides with 
decreases in core body temperature, alertness, and performance [7]. Melatonin regulates memory 
formation by directly affecting hippocampal neurons. There are antinociceptive, antidepressant, 
anxiolytic, antineophobic, and locomotor activity regulating effects of melatonin [3, 8]. Melatonin 
plays important roles in neurogenesis, neuroprotection, maintenance of oxidant/antioxidant bal-
ance, modulation of cardiovascular and/or immune system, and diabetes control. It exerts a direct 
antioxidant effect on tissues/organs and antiapoptotic effects on cells [9]. Other actions of mela-
tonin include inhibition of dopamine release in the hypothalamus and retina, involvement in the 
aging process and pubertal development, blood pressure control, and free radical scavenging [7]. 
Melatonin dysfunction may contribute to many divergent diseases, such as neurodegenerative 
diseases, circadian and mood disorders, insomnia, type 2 diabetes, and pain [3]. Low levels of 
melatonin have been shown in Parkinson’s disease (PD), Alzheimer’s disease (AD), insomnia, 
epilepsy, ischemic injury, and neuropsychiatric disorders; in addition, roles for melatonin in the 
development of cataracts, aging, and retinitis have also been reported [10]. Melatonin has been 
utilized in several countries for circadian rhythm disorders, sleep disturbances, jet lag, and sleep–
wake cycle disturbances in blind people and shift workers [7, 11, 12].
Melatonin is secreted primarily by the pineal gland in response to darkness [2, 13, 14]. It was 
later found to be also present or synthesized in extrapineal sites such as retina, Harderian 
gland, lymphocytes, gastrointestinal tract, bone marrow cells, platelets and skin [13, 15–17]. 
The neurohormone melatonin is not stored in the pineal gland but rather is released into the 
bloodstream and can penetrate all body tissues [18]. The synthesis of melatonin shows a clear 
circadian rhythm with low levels during the daytime and its secretory peak at night [19, 20]. The 
nocturnal synthesis and release of melatonin by the pineal gland are strictly controlled by the 
suprachiasmatic nucleus (SCN) clock and inhibited by lighting conditions [19, 21]. In humans 
and other mammals, detection of light drives activity in retinal ganglion cells that project to 
the SCN in the hypothalamus, causing the release of inhibitory γ-amino butyric acid that sup-
presses the circuit controlling melatonin synthesis and release [22]. Serum melatonin reaches a 
peak value (80–150 pg/mL) between midnight and 3 a.m., while its concentration during the day 
is low (10–20 pg/mL) [23]. Both normal melatonin patterns and the influence of light can vary 
considerably between individuals, either in terms of personal characteristics or as a consequence 
of aging or a chronic disease [24]. Serum concentrations of melatonin vary considerably with 
age, and infants secrete very low levels of melatonin before 3 months of age. Amplitude of the 
nocturnal peak in melatonin secretion reaches the highest levels between the 4th and 7th year of 
age [15, 19]. Other factors that alter melatonin levels are nightwork, impaired light–dark cycles, 
and obesity. Additionally, some nutritional factors could change melatonin production [13].
Melatonin, hormone of darkness, is synthesized from tryptophan, which is an essential 
amino acid by the pineal gland. The synthesis of melatonin is a multistep process. Firstly, 
tryptophan is hydroxylated by tryptophan-5-hydroxylase (TPH) to form 5-hydroxytryp-
tophan, which is subsequently decarboxylated to 5-hydroxytryptamine (serotonin) by 
L-aromatic amino acid decarboxylase (AADC). Serotonin is N-acetylated by arylalkyl-
amine N-acetyltransferase (AA-NAT, also called “Timezyme,” is the rate-limiting enzyme 
for melatonin synthesis), to form N-acetylserotonin, which is converted to N-acetyl-5-
methoxytryptamine (melatonin) by N-acetylserotonin-O-methyltransferase (ASMT, also 
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called hydroxyindole-O-methyltransferase or HIOMT). The last step is the rate-limiting step 
in the biosynthesis of melatonin (Figure 1) [18, 20, 25–28].
Melatonin synthesis depends on intact beta-adrenergic receptor function. Norepinephrine 
activates the N-acetyltransferase, and beta-receptor blockers depress melatonin secretion [29]. 
Both AA-NAT and ASMT activities are controlled by noradrenergic and neuropeptidergic pro-
jections to the pineal gland. The pineal gland receives input from postganglionic fibers, leading 
to the release of norepinephrine. Norepinephrine induces its α1/β-adrenoceptors that activate 
adenylate cyclase-cAMP system. Thus, intracellular levels of the second messengers include 
cAMP, Ca2+, phosphatidylinositol, diacetylglycerol, and protein kinase C increase. These mes-
sengers induce the expression and activity of AA-NAT and HIOMT [7, 14, 15, 18, 30].
The pineal gland is located outside the blood brain barrier, and loses it connections with the 
central nervous system, having sympathetic innervation as its main source. This may explain 
for the pineal gland ability to have a large uptake of tryptophan leading to a high melatonin 
production and secretion in response to darkness [18]. Once synthesized, melatonin is quickly 
released into the systemic circulation to reach central and peripheral target tissues. The effects 
of melatonin depend on the localization and types of melatonin receptors [15]. Melatonin 
activates two high-affinity G-protein-coupled receptors, termed MT1 and MT2. The MT1 and 
MT2 lead to an inhibition of the adenylate cyclase in target cells and regulate a variety of 
cellular and physiological processes including neuronal firing, arterial vasoconstriction, cell 
proliferation, immune responses, and reproductive and metabolic functions [8, 16, 27, 31–33]. 
MT1 and MT2 receptors are 350 and 362 amino acids long, located on chromosome 4q35.1 
and chromosome 11q21-q22, respectively. MT1 receptors are expressed in the brain, cardio-
vascular system, immune system, testes, ovary, skin, liver, kidney, adrenal cortex, placenta, 
breast, retina, pancreas, and spleen. MT2 has been found in the immune system, brain, retina, 
pituitary, blood vessels, testes, kidney, gastrointestinal tract, mammary glands, adipose tis-
sue, and the skin [27, 31, 32]. The MT3 receptor has a low affinity, unlike MT1 and MT2; it 
is not coupled to G proteins; it has a nanomolar affinity for melatonin, and it is not sensitive 
Figure 1. Biosynthesis of melatonin from tryptophan (TPH, tryptophan-5-hydroxylase; AADC, L-aromatic amino acid 
decarboxylase; AA-NAT, arylalkylamine N-acetyltransferase; HIOMT, hydroxyindole-O-methyltransferase).
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to Na+2, Mg+2, and Ca+2. The MT3 is equivalent to enzyme quinone reductase II [27]. The rela-
tionship between multiple physiological function of melatonin and this enzyme is possibly 
involved in the regulation of cellular redox status, although the exact role of this relationship 
remains unclear [16, 34]. Melatonin appears to be a natural ligand for the retinoid-related 
orphan nuclear hormone receptor family (RZR/ROR). RZR/RORα is expressed in a variety of 
organs, whereas RZRβ is specific for the brain and retina [35]. In addition, melatonin inter-
acts with intracellular proteins such as calmodulin, calreticulin, or tubulin and antagonizes 
the binding of Ca2+ to calmodulin [7]. ROR/RZR has been proposed to work in coordination 
with the plasma membrane receptors MT1/MT2 to regulate gene expression. The low-affinity 
interaction between melatonin and calmodulin may be involved in its antioxidant action as 
well as other signaling processes [15, 16]. The membrane receptors have been defined in the 
central nervous system and in peripheral organs, such as liver, gastrointestinal tract, skin, kid-
ney, heart, and adipose and lymphoid tissues in many mammalians [33]. Melatonin also acts 
through nonreceptor-mediated mechanisms, for example, serving as a scavenger for reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) [27]. Melatonin and its metabolites 
have potent antioxidative and radioprotective properties [36]. Melatonin has been proven to 
be an efficient oxidant scavenger of a variety of radical and nonradical reactants [37].
In the circulation, melatonin is partially bound to albumin and can also bind to hemoglobin 
[38]. Melatonin metabolism is a rapid process, and its half-life in humans varies between 10 
and 60 min following exogenous administration. It is deactivated mostly by the liver and 
excreted in the urine [13, 26]. There are three major pathways of melatonin degradation: (1) 
the classical hepatic degradation pathway that generates 6-hydroxymelatonin, (2) the alterna-
tive indolic pathway that produces 5-methoxyindole acetic acid (5-MIAA) or 5-methoxytryp-
tophol (5-MTOL), and (3) the kynurenic pathway that produces the main brain metabolites of 
melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), and its deformylated prod-
uct N1-acetyl-5-methoxykynuramine (AMK). These metabolites are highly remarkable and 
are generated enzymatically, pseudoenzymatically, by free radical, and via photochemical 
processes. Recently, it was reported that AFMK and AMK detoxify reactive species and pre-
serve tissues from damage by reactive intermediates [39]. This chapter summarizes effects of 
melatonin and its metabolites as antioxidants and their clinical significance in several diseases.
2. Free radicals
Free radicals are atoms or molecules that containing one or more unpaired electrons in the 
external orbitals of the molecules, usually unstable and highly reactive. The free radical 
chemical reactivity is directly associated with the damage that they can inflict to biological 
molecules. In biology system, oxygen-derived radicals and nitrogen-derived radicals are two 
types of free radicals. Oxygen-derived radicals, such as superoxide (O
2
•−), hydroxyl radicals 
(OH•), alkoxyl radicals (RO•), as well as nonradicals such as hydrogen peroxide (H
2
O
2
), ozone 
and hypochlorous acid, are defined as reactive oxygen species (ROS). ROS are produced dur-
ing the oxygen metabolism. Nitrogen-derived radicals and nonradicals, such as nitrogen 
dioxide (NO
2
), nitric oxide radicals (NO•), and peroxynitrite (ONOO), are known as reactive 
nitrogen species (RNS) which are derived from nitric oxide and superoxide by inducible nitric 
oxide synthase (iNOS) and NADPH oxidase, respectively [16, 40–44]. Oxidants are produced 
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as a result of normal intracellular metabolism in mitochondria and peroxisomes, as well as 
from diverse cytosolic enzyme systems such as lipoxygenases, NADPH oxidase, and cyto-
chrome P450. Furthermore, various external agents including ionizing radiation, ultraviolet 
light, environmental toxins, inflammatory, and cytokines can trigger ROS production [16, 44]. 
Mitochondria are the major source of ROS and RNS production [45]. Generation of O
2
•− during 
oxidative phosphorylation takes place mainly in the mitochondria. O
2
•− is quickly converted 
to H
2
O
2
 enzymatically by superoxide dismutases (SODs). After that, H
2
O
2
 is converted into 
water or highly toxic hydroxyl radical [16]. Although hydroxyl radical formation can occur in 
several ways, by far the most important mechanism in vivo is likely to be the transition metal-
catalyzed decomposition of superoxide anion and hydrogen peroxide [46]. Hydroxyl radicals 
are generated from hydrogen peroxide during cellular oxygen metabolism via the Fenton and 
Haber-Weiss reactions (Figure 2) [47], in the presence of free iron or copper ions [48]. The OH• 
is formed during the Fenton reaction when H
2
O
2
 interacts with transition metals (Fe2+, Cu1+, 
etc.) [16, 40, 41]. It can also be produced by ultraviolet and ionizing radiations [41].
Alkoxyl radicals that are formed from the reduction of peroxides, are less reactive than OH• 
and significantly more reactive than ROO radicals, provided that R is the same in both spe-
cies. Therefore, they are suggested to be ideal candidates to evaluate the efficiency of antioxi-
dants and also the reactivity of any species reacting with ROS. As regards RNS, the chemical 
reactivity and direct toxicity of NO• are quite low. However, it reacts with O
2
•− forming per-
oxynitrite, which is a powerful oxidant. NO
2
 is a mild oxidant, and its reactivity is between 
those of NO• and ONOO− [41, 42, 44].
In healthy organisms, there is a delicate balance between the production and the removal 
of free radicals, which guarantees that they remain in low/moderate concentrations. Under 
such conditions, free radicals have beneficial effects [41]. ROS and RNS play important roles 
in regulation of a wide variety of physiology functions like gene expression, cellular growth, 
differentiation, modulation of chemical reactions, and induction of transcription factors such 
as nuclear factor-kappa B (NF-кB) and activator protein-1 (AP-1) and activation of signal 
transduction pathways. They also participate in blood pressure control, are mediators in 
the biosynthesis of prostaglandins, function in embryonic development, and act as signal-
ing molecules within the individual cell and among cells during their life span [44–46]. The 
harmful and useful effects of ROS/RNS are associated with their concentrations, the cell type 
and the subcellular compartments that are produced, and their timing of production [16]. An 
imbalance between excessive ROS and RNS generation and rate of their elimination by the 
antioxidant capacity leads to oxidative stress [49, 50]. It has been shown that oxidative stress 
is involved in over 100 diseases, as their cause or consequence [51]. Oxidative stress results 
in macromolecular damage and is implicated in various disease states such as atherosclero-
sis, diabetes, cancer, neurodegeneration, and aging [52]. The cellular dysfunctions caused by 
excessive ROS and/or RNS might produce loss of energy metabolism, altered cell signaling 
Figure 2. Fenton and Haber-Weiss reactions.
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and cell cycle, gene mutations, and impaired cellular transport mechanisms. The oxidative 
stress promotes decreased biological activities, immune activation, and inflammation [50]. It 
seems that both high levels of ROS (oxidative stress) and excessively low levels of ROS (reduc-
tive stress) are deleterious and apparently play a causative role in the pathologies caused by 
malfunctioning processes related to the dramatic change of redox environment [53].
3. Antioxidants
Based on the oxidative stress related to free radical theory, the antioxidants are the first line of 
choice to take care of the stress [45]. Antioxidants act as free radical scavengers and can prevent 
oxidative reactions that lead to various diseases [54]. The antioxidant defense system includes 
endogenous (enzymatic and nonenzymatic) and exogenous (dietary) antioxidants that interact in 
establishing redox homeostasis in the body [49]. Endogenous antioxidants, which are products 
of the body’s metabolism, may be enzymatic or nonenzymatic compounds localized generally in 
the cytoplasm and diverse cell organelles [45, 49]. In eukaryotics, various antioxidant enzymes, 
for instance, SOD, catalase (CAT), and some peroxidases, transform ROS into more stable 
molecules (e.g., water and O
2
) via complex cascade of reactions [45]. One of the most effective 
intracellular enzymatic antioxidants is SOD. In humans, there are three forms of SOD: cytosolic 
CuZn-SOD, mitochondrial Mn-SOD, and extracellular SOD. SOD catalyzes the dismutation of 
O
2
•− to H
2
O
2
, decreasing the amount of O
2
•− and thereby lowering the formation of ONOO− [44, 
50]. Other important enzymatic antioxidants include CAT, glutathione peroxidase (GPx), gluta-
thione reductase (GR), and peroxiredoxins (Prxs). These enzymes neutralize hydrogen peroxide, 
yielding water (CAT, GPx) and oxygen molecule (CAT) [45, 49]. CAT which is found in the per-
oxisomes and cytoplasm [55] presents a molecule of ferric ion at its active site and converts two 
molecules of H
2
O
2
 into one molecule each of water and diatomic oxygen [37]. Glutathione peroxi-
dase can be found in many subcellular compartments including the mitochondria and nucleus 
depending on the family member [55]. Selenium, as a selenocysteine, is a component of the active 
site of GPx [37, 55, 56]. GPx uses reduced glutathione (GSH) as a substrate to transfer electrons 
to H
2
O
2
 (and other peroxides), thereby converting it into two molecules of water [37]. When 
hydrogen peroxide is metabolized by glutathione peroxidase, reduced glutathione is oxidized to 
glutathione disulfide (GSSG) which is converted back to GSH by the enzyme GR [57–59].
Small molecular nonenzymic antioxidants (e.g., GSH, NADPH, thioredoxin, vitamin E 
(α-tocopherol), vitamin C (ascorbic acid), and trace metals, such as selenium) also function as 
direct scavengers of ROS [45]. In particular, glutathione plays a central role in defense against 
oxidative stress [54]. The antioxidant properties of GSH which is a tripeptide, γ-l-glutamyl-
l-cysteinyl-glycine, depend on the presence of a peptide bond between the amino group of 
cysteine and the alpha-carboxyl group, which provide an excellent protection against ami-
nopeptidases, and the expression of the thiol group which derive from the cysteine residue. 
Complexation of metal ions, participation in the oxidation reactions, and formation of thiol 
radicals and disulfides are the most important functions of thiol groups in the biological sys-
tems [49]. Maintaining or reestablishment of redox homeostasis are ensured by endogenous 
and exogenous antioxidants that act synergistically [49, 60], such as during the regeneration 
of vitamin E by GSH or vitamin C to prevent lipid peroxidation, which can affect membrane 
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fluidity and damage membrane proteins [60, 61]. Vitamin E and Vitamin C are the most fre-
quently used antioxidant vitamins [62] that are thought to have a protective effect by either 
reducing or preventing oxidative damage [63]. Vitamin E belongs to the group of fat-soluble 
vitamins existing in eight different forms. The methylation pattern of the chroman ring deter-
mines the classification as α, β, γ, and δ tocopherols. These compounds have antioxidant 
properties. Vitamin E scavenges peroxyl radicals and hence acts to break the chain reaction 
of lipid peroxidation [64]. Besides its antioxidant role, vitamin E might also have a structural 
role in stabilizing membranes [46, 65, 66]. Vitamin C, which is readily water soluble, is an 
important antioxidant and thus works in aqueous environments of the body [46, 57, 67]. As an 
antioxidant, ascorbate is an efficient scavenger, or reducing antioxidant, capable of donating 
its electrons to ROS and eliminating them [44]. Loss of one electron generates the ascorbyl 
radical intermediate, and loss of two electrons generates dehydroascorbate (DHA, which can 
also be formed via dismutation of the ascorbyl radical) [61, 68]. It makes ascorbate a powerful 
important antioxidant [44]. Vitamin C serves as a co-antioxidant with vitamin E to regenerate 
α-tocopherol from α-tocopherol radicals in membranes and lipoproteins and protect protein 
thiol group against oxidation by increasing intracellular levels of GSH [46, 61, 69]. Vitamin C 
can also neutralize ROS (e.g., hydrogen peroxide) [46, 70]. Recently, toxicity of ascorbic acid 
has also been attributed to its autoxidation [45].
An efficient antioxidant should not only be ubiquitous but should also be present in adequate 
amounts in cells and easily reacts with a wide variety of free radicals which have short half-
life due to high reactivity. A good antioxidant has the ability to cross physiologic barriers 
and to be quickly transported into the cells. Thus, it must be available to all cells. It is also 
important for an antioxidant to be available. Antioxidants should be available when needed. 
They should be easily acquired through the diet or produced in situ. Antioxidants should 
be suitable for regeneration. The reaction between an antioxidant and a free radical yields 
an oxidized form of the antioxidant which has less scavenging activity than the original 
compound. Therefore, many antioxidants have physiologically reducing mechanisms, or its 
oxidized forms can still efficiently react with new free radicals. An ideal antioxidant should be 
conserved by the kidneys. Otherwise, large urinary losses would occur and the half-life will 
be short. An important aspect to consider for evaluating the suitability of a compound as an 
antioxidant is its toxicity. It should be nontoxic prior to and after the free radical scavenging 
process takes place. In addition, it is also important to be aware of possible interactions with 
any drug that may be concurrently consumed [41, 71, 72].
Melatonin is a potent direct scavenger of free radicals. Unlike most of other radical scaven-
gers, it is a multifunctional antioxidant. Melatonin can easily pass through cell membranes 
because of its high lipophilicity and hydrophilicity [73]. Melatonin is also widespread within 
cells. Its concentrations in human serum and cerebrospinal fluid vary widely. Melatonin is 
endogenously generated, and it is ingested in the food as it is widely available in fruits and 
vegetables. Hence, melatonin is produced internally and is also ingested in the diet. Only 
small amounts of melatonin are excreted into the urine in its unchanged form. It has minimal 
toxicity. Numerous in vivo studies on animals involving massive doses of melatonin have 
shown that acute and chronic toxicity of melatonin is extremely low [41, 74]. Unlike most 
small molecule biological antioxidants such as ascorbic acid, α-tocopherol, lipoic acid, etc., 
melatonin does not undergo redox cycling and, thus, does not promote oxidation. Melatonin 
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can be considered a suicidal or terminal antioxidant. It undergoes molecular rearrangement, 
effectively removing the free electron from the system. Each of these products of rearrange-
ment is also a potent antioxidant in its own right. Furthermore, most of these processes 
involve more than one ROS per step, so that one melatonin molecule has the capacity to 
scavenge up to 10 ROS versus the classic antioxidants that scavenge one or less ROS [17, 
20, 70, 74]. It has been found that melatonin promotes the repair of oxidized DNA. This is 
probably due to the melatonin’s capability of transforming guanosine radical to guanosine 
by electron transfer [42]. It was shown that melatonin reduced the formation of 8-hydroxy-2′-
deoxyguanosine (8-OH-dG), a damaged DNA product, 60–70 times more effective than some 
classic antioxidants (ascorbate and α-tocopherol) [75]. Additionally, the relative position of 
melatonin and its metabolites in the antioxidant “pecking order” (electrochemical potential) 
may contribute greatly to its utility in biological systems [76]. Melatonin protects lipids, pro-
teins, and nuclear DNA from oxidative damage suggests that its intracellular distribution 
is wide [17]. Melatonin turned out to be considerably more efficient than the majority of its 
naturally occurring structural analogs, indicating that the substituents of the indole moiety 
strongly influenced reactivity and selectivity [77].
4. Melatonin and its metabolites as antioxidants
Melatonin is an indoleamine with two side chains, a 5-methoxy group and 3-amide group. Its 
molecular weight is 232.2 g/mol [42]. Melatonin has multifunctional activities in addition to its 
function as a synchronizer of the biological clock and seasonal reproduction [78, 79]. One such 
activity is its antioxidant capacity. Melatonin and its metabolites were found to have important 
antioxidant properties owing to their direct and indirect antioxidant actions. Melatonin can 
easily cross cell membranes [80] and the blood brain barrier [78] and protects various biomol-
ecules against damage caused by free radicals by acting as a direct scavenger to detoxify reac-
tive oxygen and nitrogen species. In addition, melatonin can indirectly reduce oxidative stress 
by increasing the activities of antioxidative defense systems; stimulating the expression and 
function of a number of antioxidant enzymes, as well as glutathione, another very important 
nonenzymatic, low molecular weight antioxidant; interacting synergistically with other anti-
oxidants; and increasing the efficiency of the mitochondrial electron transport chain [40, 78–82]. 
Also, melatonin has a chelating property which may contribute in reducing metal-induced 
toxicity [83]. Melatonin was shown to be much more specific than its structural analogs in 
undergoing reactions, which lead to the termination of the radical reaction chain and in avoid-
ing prooxidant, C- or O-centered intermediates [33, 38]. Moreover, it has been shown that it has 
an ability to scavenge free radicals, including hydroxyl radicals, hydrogen peroxide, peroxyl 
radicals, singlet oxygen, nitric oxide, and peroxynitrite. It was demonstrated that melatonin 
inhibits the activity of NO synthase, beside it’s NO and peroxynitrite scavenging activity [84].
Melatonin, an endogenously produced indoleamine, is a highly effective antioxidant and free 
radical scavenger [82]. Melatonin has been reported to neutralize the most toxic oxidizing 
agents, hydroxyl radical and the peroxynitrite anion, generated within the cells. Moreover, 
melatonin reportedly scavenges singlet oxygen (1O
2
), superoxide anion radical, hydrogen per-
oxide, nitric oxide, and hypochlorous acid (HClO) [17]. Due to the electron-deficient nature of 
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halide ions, haloperoxyl radicals are significantly more reactive than the alkylperoxyl radical; 
accordingly, the trichloromethylperoxyl radical (CCl
3
OO•) was found to be potently trapped 
by melatonin [85]. Not only melatonin but also several of its metabolites that are formed 
when it functions as a direct free radical scavenger, i.e., cyclic 3-hydroxymelatonin (c3OHM), 
AFMK, AMK, etc., are also radical scavengers [57, 86]. Melatonin and its metabolites work in a 
“task-division” way, with some of them acting mainly as free radical scavengers, while others 
act as metal chelating agents and inhibitors of the hydroxyl radical (OH•) production [87]. 
The sequential scavenging of ROS by melatonin and its metabolites is known as melatonin’s 
antioxidant cascade [16]. The efficiency of AMK for scavenging ROS and preventing protein 
oxidation has been reported to be higher than that of AFMK. Therefore, it seems that at least 
in general, their protective activities against oxidative stress follow the order AMK > melato-
nin > AFMK [88] (Table 1).
4.1. Effects of melatonin and its metabolites on reactive oxygen species
Electron donation is the principal mechanism by which melatonin detoxifies the free radicals 
[17]. While melatonin has the capability of donating one or more electrons to free radicals 
resulting in their detoxification, the metabolites that are formed during this process, i.e., 
c3OHM, AFMK, and AMK, also have similar capabilities [90]. After donating an electron to 
OH•, melatonin becomes a free radical itself, the indolyl radical cation. However, its reactivity 
is very low, and, therefore, it is not toxic to cells [41]. Oxidation of melatonin by hydroxyl 
radicals leads to several hydroxylated products which can be explained by interaction of 
melatonin with two hydroxyl radicals, one acting by hydrogen abstraction and the other by 
combining with the reaction partner especially, at the sides C2, C3, C6, and C7 [91].
6-Hydroxymelatonin (6OHM) is the major hepatic metabolite and photodegradation product 
of melatonin. It is an efficient metabolite for protecting against oxidative damage induced by 
UV irradiation. Due to its capability of scavenging 1O
2
 and O
2
•−, 6OHM can reduce neurotoxic-
ity induced by quinolinic acid. It also lowers Fe(II)-induced neurotoxicity and iron-induced 
lipid peroxidation. It also inhibits the oxidative damage induced by this metal, UV radiation, 
thiobarbituric acid, and cyanide. It may be more efficient than melatonin in this capacity. 
Moreover, it inhibits oxidative stress induced by Cu+2-ascorbate mixtures and OH• produc-
tion by sequestering Cu+2 ions. 6OHM also protects DNA damage induced by Fenton reagents 
and UV radiation [84, 92].
It was showed that the main hydroxylated metabolite of melatonin interaction with hypochlorous 
acid is 2-hydroxymelatonin (2OHM). Subsequently, 2OHM and its keto tautomer, melatonin 
2-indolinone, were the oxidative products of melatonin’s interaction with oxoferryl hemoglobin 
or OH• [93]. 4-Hydroxymelatonin (4OHM) is an excellent peroxyl radical scavenger and also a 
preventing antioxidant by inhibiting Cu(II). This effect would reduce the Cu(I) availability, which 
is the redox state required for the OH• to be formed, via Fenton-like reactions. 4OHM terminates 
the oxidant effects of copper-ascorbate mixtures. The key structural feature in the antioxidant 
activity of 4OHM is the presence of phenolic group, unlike 2OHM which has a relative low anti-
oxidant protection [94]. 4OHM and 2OHM are generated during the UV-induced metabolism of 
melatonin. Further investigation needs to understand the antioxidant activity of these two com-
pounds, as well as their potential role in protecting biomolecules against oxidative damage [87].
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7-Hydroxymelatonin has been rarely considered, although the calculated activation energy for 
the respective reaction is as low as that for 6-hydroxylation. 3-Hydroxylation leads to an unusual 
compound cyclic 3-hydroxymelatonin (c3-OHM) [91]. c3-OHM is an intermediate metabolite 
of melatonin [16]. c3-OHM effectively scavenges OH•, ABTS•+ (2,20-azino-bis(3-ethylbenzthia-
zoline-6-sulphonic acid)) [95], and peroxyl radicals [96] and can also chelate Cu(II), preventing 
its reduction and the consequent OH• production via Fenton-like reactions [93, 97]. It is demon-
strated that c3-OHM inhibits oxidative DNA damage and 8-OHdG lesions, induced by Fenton 
reagents, under in vitro conditions [98]. Indeed, c3-OHM is considered a footprint molecule, 
excreted in small amounts in the urine, and evidence of the in vivo scavenging activity of mela-
tonin [41]. c3-OHM also undergoes oxidation resulting in the formation of AFMK [16, 77, 99].
AFMK is one of the metabolites of melatonin and can be formed by both enzymatic or pseudo-
enzymatic and nonenzymatic metabolic pathways [10, 88]. Pyrole ring cleavage of melatonin 
by varied enzymes including indoleamine 2,3-dioxygenase (IDO), myeloperoxidase (MPO), 
and hemoperoxidases, varied pseudoenzymatic catalysts such as oxoferryl hemoglobin and 
in varied reactions with ROS involving free radicals and singlet oxygen, generates AFMK 
[39, 88, 100]. Melatonin oxidation by MPO and IDO generally requires O
2
•− that produced in 
large amounts in inflammatory circumstances [100]. Besides, there are also multiple hydrox-
ylations, which are formed in the peroxidase and peroxidase-like reactions and in the conver-
sion of c3-OHM to AFMK [39]. Nonenzymatically, direct reaction of melatonin with highly 
reactive oxygen species (e.g., hydroxyl radical and singlet oxygen) formed AFMK [100]. The 
formation of AFMK by singlet oxygen deserves attention, as this reactive oxygen species is 
formed under the influence of UV light [101]. In light of these findings, it appears that AFMK 
is a product common to several interactions of melatonin with oxygen-based reactants [85]. 
The generation of AMK occurs via deformylation of AFMK [10, 16, 77]. These compounds 
are also major melatonin metabolites in detoxifying ROS and reducing oxidative stress 
ROS/RNS neutralized by melatonin and its 
metabolites
Antioxidative enzymes that are stimulated by  
melatonin
Hydroxyl radical Superoxide dismutase
Hydrogen peroxide Glutathione peroxidase
Superoxide anion radical Catalase
Nitric oxide Glutathione reductase
Alkoxyl radical Glutamyl-cysteine ligase
Peroxynitrite Cyclooxygenase
Singlet oxygen Heme oxygenase
Hydrogen peroxide Nitric oxide synthase
Hypochlorous acid Paraoxonase
Others Myeloperoxidase
Lipoxygenase
Table 1. Antioxidant effects of melatonin and its metabolites [89].
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[10, 16]. AFMK is obviously more stable than many other oxidative metabolites or its sec-
ondary product, AMK [39]. AFMK reduces lipid peroxidation and oxidative DNA damage 
induced by a variety of oxidative stressors under various conditions [16]. It protects neuronal 
cell from injuries caused by hydrogen peroxide and amyloid-β (Aβ) peptide [85, 88, 93]. It has 
been suggested that neuroprotection of AFMK against radiation-induced oxidative damage 
to the brain is due to its free radical scavenging function [88].
Lipid peroxidation is a natural metabolic process under normal aerobic conditions, and it is one 
of the most investigated consequences of ROS action on membrane structure and function [44]. 
Alterations in the fluidity of membranes result in negative effects on their functions such as signal 
transduction processes and implicate in aging as well as in diseases [102]. Melatonin is known 
to be a stabilizer or protector of cell and organelle membranes because of its inhibitory effects on 
lipid peroxidation. Melatonin and its metabolites scavenge free radicals and thus terminate the 
initiation and propagation of lipid peroxidation [103]. Although melatonin and its metabolites, 
AFMK and AMK, are peroxyl radical scavengers, it is indicated that melatonin’s ability to resist 
lipid peroxidation may also involve its metabolite, c3-OHM [104]. For the reaction with the per-
oxyl radical, c3-OHM was several orders of magnitude faster than melatonin, AFMK and AMK, 
and it was roughly 100-fold faster than water soluble vitamin E (Trolox) [96, 105]. Melatonin also 
directly scavenges the alkoxyl radical, a product resulting from the transition metal-catalyzed 
degradation of lipid peroxides. This is important for the control of lipid peroxidation since the 
alkoxyl radical can abstract a hydrogen atom from a polyunsaturated fatty acids; the resulting 
peroxyl radical can obviously continue the propagation of lipid degradation [104, 106].
4.2. Effects of melatonin and its metabolites on reactive nitrogen species
Reactive nitrogen species represent another category of potentially destructive substances, 
which react with melatonin [77]. ONOO• itself is a very damaging species able to react with 
proteins, lipids, and DNA. Therefore, the reaction between two rather innocuous free radi-
cals produces a much more reactive one [41]. Melatonin readily combines with a superoxide 
releasing NO, thus preventing the formation of peroxynitrite, a free radical even more harm-
ful than NO. It has been described as a direct peroxynitrite scavenger [40].
Scavenging of nitric oxide by melatonin in a nitrosation reaction is well documented. Whether 
this can be regarded as a detoxification reaction keeping NO from forming, the more danger-
ous peroxynitrite is uncertain because nitrosomelatonin easily decomposes, thereby releasing 
NO. Melatonin also scavenges peroxynitrite, but it is difficult to discriminate direct reactions 
with peroxynitrite and with hydroxyl radicals generated by decomposition of peroxynitrous 
acid. The interaction with products from the peroxynitrite-CO
2
 adduct (ONOOCO
2
−) which 
carbonate radicals (CO
3
•−) and NO
2
• seems to be more important than direct scavenging of 
peroxynitrite [33, 77]. There is evidence for the formation of cyclic 2-hydroxymelatonin, cyclic 
3-hydroxymelatonin, and 6-hydroxymelatonin about the reaction of melatonin with ONOO−. 
It was suggested that one electron is transferred from melatonin to ONOO− in the melato-
nin +ONOO− reaction and/or nitrated intermediates occur in the oxidation. In addition, the 
6-hydroxymelatonin is not generated in the presence of CO
2
. Therefore, it was suggested that 
formation of 6-hydroxymelatonin required an activated peroxynitrite that can only exist in 
the absence of bicarbonate [41, 107, 108]. AFMK has the ability to interact with the ABTS 
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cation radical as well as with ROS/RNS to form AMK. When AMK interacts with the ABTS 
cation radical or with ONOO−, it forms products that may also be ROS and RNS scavengers 
[59]. AMK was described as better a NO scavenger than melatonin or AFMK [88]. AMK effec-
tively inhibits neuronal nitric oxide synthase activity and reduces intracellular NO levels [93].
4.3. Effects of melatonin and its metabolites on antioxidant enzymes
Cells are protected against oxidative stress by an interacting network of antioxidant enzymes 
[70]. Antioxidative enzymes provide a major defense mechanism against free radical dam-
age either by metabolizing them to less reactive species or to nontoxic by-products [85]. The 
activities of antioxidative enzymes depend on the duration and severity of oxidative stress. 
Under prolonged oxidative stress conditions, free radicals directly damage the antioxidant 
enzymes or reduce enzyme activities [90, 109]. Besides its ability to directly neutralize a num-
ber of free radicals and reactive oxygen and nitrogen species, melatonin stimulates several 
antioxidative enzymes which increase its efficiency as an antioxidant [58]. The major anti-
oxidative enzymes such as intracellular superoxide dismutases (CuZn-SOD and Mn-SOD), 
the selenium-containing glutathione peroxidases and catalase, are stimulated by melatonin 
under basal conditions [43, 75, 110]. Melatonin plays a significant role in maintaining indirect 
protection versus free radical injury by stimulating gene expression of antioxidant enzymes 
including those for SOD and GSH-Px [43, 58, 62, 111]. Melatonin affects both antioxidant 
enzyme activity and cellular mRNA levels for these enzymes under physiological circum-
stances and during increased oxidative stress, presumably through epigenetic mechanisms. 
These properties in a single molecule are unique for an antioxidant, and both actions protect 
against pathologically generated free radicals [43, 62].
The concentration of the intracellular antioxidant, glutathione, is very high in many cells. During 
high oxidative stress conditions total glutathione levels can be reduced [90]. Melatonin main-
tains the activities of enzymes that enhance intracellular levels of reduced GSH. The recycling 
of GSH may well be a major effect of melatonin in reducing oxidative stress. GSH is oxidized to 
its disulfide, GSSG, which is then quickly reduced back to GSH by GR, an enzyme which has 
been demonstrated to be stimulated by melatonin. The ability of melatonin to regulate the GSH/
GSSG balance by modulating enzyme activities seems to involve an action of melatonin at a 
nuclear binding site [85, 112]. The other GSH-metabolizing enzyme, i.e., CAT, also increases its 
activity in response to melatonin [85]. Furthermore, one of the melatonin actions is stimulation 
of gamma-glutamylcysteine synthetase that is the rate-limiting enzyme in glutathione produc-
tion, thus glutathione levels do not drop significantly [36, 43, 58, 75, 77, 85, 86, 90, 110, 112, 113].
There are a number of prooxidative enzymes in multicellular organisms which gener-
ate free radicals [90]. Melatonin not only upregulates the expression of genes involved in 
detoxifying free radicals, but it also suppresses the activity or expression of genes involved 
in the generation of free radicals [16, 113]. Melatonin inhibits the prooxidative enzyme nitric 
oxide synthase which generates NO• and lipoxygenase which result in the formation of the 
superoxide anion [90, 113, 114]. Although NO• is not a strong free radical, when it couples 
with O
2
•−, it forms the peroxynitrite anion which is potently reactive and damaging [90]. 
Lipoxygenase reaction is another possible source of ROS and other radicals. It catalyzes the 
hydroperoxidation of polyunsaturated fatty acids [115]. The prooxidative enzymes inhibited 
by melatonin also include myeloperoxidase and eosinophil peroxidase [110]. As a result, 
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free radical and/or toxic reactant generation is alleviated [90, 114]. In addition, AFMK and AMK 
also have the ability to downregulate prooxidative and pro-inflammatory enzymes including 
iNOS [102] and cyclooxygenase-2 (COX-2) and to carry out free radical avoidance functions [93].
4.4. Effects of melatonin and its metabolites on the mitochondria
Mitochondria are critical in the control of metabolism and responsible for orchestrating cel-
lular energy production. Therefore, they are central to the maintenance of life and the gate-
keepers of cell death [116]. The production of energy in the form of ATP is crucial to optimal 
cell function, including aiding in repairing any cellular damage that has occurred and in 
improving survivability of the cell, of the tissue, and of the organism [90]. Up to 95% of the 
ATP produced in aerobic cells is a result of mitochondrial oxidative phosphorylation [59]. 
The ETC which is coupled to oxidative phosphorylation [59] is a system of oxidoreductase 
protein complexes (complexes I, II, III, and IV) [85]. Deficiencies in the ETC can result in the 
leakage of electrons which thereafter generate free radicals and other toxic reactants which 
leads to molecular damage in mitochondria; this damage culminates in and promotes what 
are referred to as mitochondria-related diseases [85]. Mitochondria are the primary source 
of free radicals [44, 45]. Increased free radical generation, enhanced mitochondrial iNOS 
activity, enhanced NO production, decreased respiratory complex activity, impaired electron 
transport system, and opening of mitochondrial permeability transition pores have all been 
suggested as factors responsible for impaired mitochondrial function [117].
Melatonin has important actions at the level of mitochondria [85]. Melatonin exhibits remarkable 
functional versatility to protect the morphological and functional aspects of the cell membrane 
scavenging free radicals, enhancing the activity of the antioxidant enzymes, and optimizing the 
transfer of electrons through the ETC in the inner mitochondrial membrane [118]. Melatonin 
increases the efficiency of the ETC and thus reduces electron leakage and free radical generation 
[38, 75, 105] that is a consequence of the respiratory process by stimulating complex I and com-
plex IV of the mitochondrial respiratory chain that are involved in oxidative phosphorylation [38, 
58, 59, 118]. By directly detoxifying ROS/RNS, melatonin enhances ATP production via maintain-
ing high levels of mitochondrial GSH, protects mitochondrial proteins and DNA from oxidative 
damage, and improves ETC activity [16, 90, 118]. Moreover, AMK, like its precursor melatonin, 
promotes mitochondrial complex I activity to elevate ATP production by lowering electron leak-
age and inhibiting the opening of the mitochondrial permeability transition pore [93].
4.5. Effects of melatonin and its metabolites on transition metals
Heavy metals are known to cause oxidative deterioration of biomolecules by initiating free 
radical-mediated chain reaction resulting in lipid peroxidation, protein oxidation, and oxi-
dation of nucleic acid like DNA and RNA [119]. The ability of antioxidants to chelate and 
deactivate transition metals prevents such metals from participating in the initiation of lipid 
peroxidation and oxidative stress through metal-catalyzed reaction [120]. Chemical mean of 
inhibiting metal-induced oxidation is chelation. This particular process is directly involved 
in the OH•-inactivating ligand (OIL) behavior of antioxidants. There are two different ways 
of action in the protection exerted by OIL species against OH•-induced oxidative damage: (i) 
inhibiting the reduction of metal ions; thus, their reduced forms are not available for Fenton-
like reactions or (ii) deactivating OH• after being produced by Fenton-like reactions [87].
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Melatonin is able to prevent the oxidative actions of metals by neutralizing the produced 
ROS and capturing such metals to form chelates [83]. It was demonstrated that the inter-
play of melatonin with metals such as aluminum, cadmium, copper, iron, lead, and zinc 
depended on concentration. Melatonin chelates both iron(III) and iron(II), which is the form 
that attends the Fenton reaction. If iron is bound to a protein (e.g., hemoglobin), melato-
nin restores the highly covalent iron such as oxyferryl (FeIV-O) hemoglobin back to iron(III), 
thereby reestablishing the biological activity of the protein [89]. It is suggested that, under 
physiological circumstances, direct chelation mechanism would be the major chelation route 
for Cu(II). It was demonstrated that melatonin and its metabolites, 3OHM, AFMK, and AMK, 
fully inhibited the oxidative stress induced by Cu(II)-ascorbate mixtures, via Cu(II) chelation 
[97]. Melatonin decreases the Cu(II)/H
2
O
2
-induced damage to proteins and protects against 
copper-mediated lipid peroxidation, which led to the suggestion that the antioxidant and 
neuroprotective effects of melatonin may involve removing toxic metals from the central 
nervous system [42].
5. Melatonin and its metabolites as anti-inflammatory agents
Inflammation is an essential response to tissue injuries induced by physical, chemical, or bio-
logical insults [17]. The production of inflammatory cytokines including TNF-α (tumor necro-
sis factor-α), IL-1β (interleukin-1β), or IL-6 attenuates by melatonin in numerous experimental 
models of inflammation [2]. Melatonin has several additional anti-inflammatory effects, which 
are probably related to a direct interaction with specific binding sites located in lymphocytes 
and macrophages [103]. Anti-inflammatory activity of melatonin includes inhibition of the acti-
vation of COX-2 and iNOS, as well as blocking of the transcriptional factors that triggers pro-
inflammatory cytokine production. These include not only NF-кB but also HIF, Nrf2, cAMP, 
CREB, STAT, PPARs, and AP-1 [2, 43, 121]. Melatonin may be useful for the treatment of inflam-
matory disease, as it reduces inflammatory injury by blocking transcription factors and NF-κB, 
thereby decreasing further ROS formation within cells [43]. In peripheral monocytes, melatonin 
and, even more, AFMK suppressed TNF-α and IL-8 production and, in macrophages, COX-2 
and iNOS expression. Moreover, melatonin was found to be efficiently oxidized to AFMK by 
macrophages [91]. AMK was reported to downregulate COX-2—but not COX-1—expression in 
macrophages, an effect shared by its precursors AFMK and melatonin [122].
6. The clinical significance of melatonin
Melatonin plays important roles in neurogenesis, neuroprotection, maintenance of oxidant/
antioxidant balance, and modulation of cardiovascular and/or immune system. It also exerts 
a direct antioxidant effect on tissues/organs and antiapoptotic effects on cells [9]. Melatonin 
has been investigated in a wide range of diseases, such as neurodegenerative, cardiovascular, 
liver, and kidney diseases, cancer, and diabetes [43].
Melatonin is a ubiquitously acting direct free radical scavenger and also an indirect antioxidant. 
Melatonin and its metabolites are efficient in scavenging ROS and RNS. It plays an effective role 
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in regulating mitochondrial homeostasis [33, 38]. Mitochondrial dysfunction, i.e., cell energy 
impairment, apoptosis, and overproduction of ROS, is a final common pathogenic mecha-
nism in aging and in neurodegenerative disease [43, 123]. Melatonin may be possible to treat 
neurodegenerative disorders by inhibiting mitochondrial cell death pathways. It may easily 
protect brain mitochondrial membranes from free radical attack, stabilizing them. The ability 
of melatonin to prevent GSH loss probably reflects its effect on the activities of the GSH redox 
cycle enzymes [33, 38, 83, 103]. Moreover, several neurological diseases including Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, and Wilson’s disease (hepatolenticular 
degeneration) are characterized by an overload of copper and/or other metals. Melatonin and 
its metabolites, c3OHM, AFMK, and AMK, have the copper sequestering ability [89].
Excessive and/or sustained increase in ROS generation plays a pivotal role in the initiation, 
progression, and clinical consequences of cardiovascular diseases (CVDs) [64, 124]. Clinically, 
melatonin is being increasingly recognized in the pathophysiology of CVD. Low levels of 
serum melatonin as well as its urinary metabolite, 6-sulphatoxymelatonin, have been 
reported in various CVDs including coronary heart disease, angina, congestive heart failure, 
and myocardial infarcts [125]. Melatonin plays an important role in the regulation of several 
parameters of the cardiovascular system, including blood pressure, and is considered to be a 
putative antihypertensive agent [126]. It may have cardio-protective properties via its direct 
free radical scavenger activity and its indirect antioxidant activity together with its signifi-
cant anti-inflammatory properties [127, 128]. Mitochondrial respiration, mainly at the level 
of complex I and complex III, is an important source of ROS generation and hence a potential 
contributor of cardiac reperfusion injury [129]. Most of the beneficial actions of melatonin at 
the heart level may depend on its effect on mitochondrial bioenergetics mediated through 
various mechanisms including general antioxidant actions at the level of ETC dysfunction, 
electron leakage, and mitochondrial oxidative damage and also through a direct action of 
melatonin on mitochondrial permeability transition pore opening [127]. It was reported 
that melatonin protects against mitochondrial dysfunction associated with cardiac ischemia 
reperfusion, by preventing alterations to several parameters involved in mitochondrial bio-
energetics [17].
Melatonin may also exhibit anticancer and protective oncostatic activity through several 
mechanisms, including inhibition of cancer cell proliferation, decrease in oxidative stress, and 
increase in immune system activity [130, 131]. Oxidative stress has complex and different 
effects on each type of cancer development [132]. Oxidation of cellular lipids and proteins can 
adversely affect several steps of the carcinogenic process through changes in a variety of cell 
regulatory functions, including signal transduction and gene expression. ROS are postulated 
to be involved in carcinogenesis process, especially in the stages of initiation and promo-
tion [133]. It appears that the DNA damage is predominantly linked with the initiation pro-
cess [132]. Free radicals and ROS generated by environmental carcinogens, or by metabolic 
alterations, cause DNA damage and genetic instability [134]. Furthermore, DNA damage, 
apoptosis resistance, enhanced proliferation, mutation, COX-2 upregulation, oxidative stress, 
tumor vascularity, and metastatic potential may be caused by nitric oxide synthase overex-
pression and increased nitric oxide and other RNS productions [132]. A growing body of 
evidence implicates melatonin’s antioxidant/free radical scavenging actions in the inhibition 
of cancer development and growth [75]. Melatonin is a powerful scavenger of ROS, such as 
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hydroxyl radical, peroxyl radical, singlet oxygen, and nitric oxide, as well as a stimulator of 
the antioxidant enzymes, SOD, GPx, and CAT, all leading to a decrease in DNA damage [135]. 
Additionally, this indole stimulates antioxidant enzymes that remove ROS before they can 
inflict damage and aids in the repair of damaged DNA [136]. Melatonin could be an excellent 
candidate for the prevention and treatment of several cancers, such as breast cancer, prostate 
cancer, gastric cancer, and colorectal cancer [137].
A variety of antioxidants protect the liver from free radical-mediated damage, one of the best 
of which is melatonin. Clinical studies have confirmed that melatonin protects the liver from 
nonalcoholic liver disease and also during the surgical procedure of partial liver resection 
[138]. Melatonin is a well-known natural antioxidant and has many bioactivities. Melatonin 
exerts antioxidant effects in hepatocytes and epithelium of the liver by reducing lipid peroxi-
dation and increasing the level of reduced liver glutathione. Melatonin is a highly valuable 
OH and H
2
O
2
 scavenger, during its metabolism to AFMK. It also induces several antioxida-
tive enzymes such as glutathione peroxidase, glutathione reductase, and SOD and increases 
the synthesis of GSH [2, 88]. Melatonin exhibits potent anti-inflammatory, antioxidant, and 
fibrosuppressive activities against thioacetamide-induced hepatic fibrogenesis via the sup-
pression of oxidative stress, DNA damage, pro-inflammatory cytokines, and fibrogenic gene 
transcripts [139]. Melatonin protects against lipid-induced mitochondrial dysfunction in 
hepatocytes and inhibits stellate cell activation during hepatic fibrosis in mice [140].
Inflammation and increased oxidative stress are also common features in chronic kidney dis-
ease patients [130, 141]. Oxidative stress and inflammation promote renal injury via damage 
to molecular components of the kidney by different mechanisms of action. ROS lead to the loss 
of significant functional properties, lipid peroxidation of cell membrane, decrease membrane 
viability, and cleavage, and cross-linking of renal DNA occurs leading to harmful mutations 
by oxidizing amino acids in the nephron. Furthermore, other ROS interactions in the nephron 
increase secondary radical production [130, 142]. Diabetes-associated hyperglycemia leads to 
mitochondrial ETC dysfunction culminating in a rise in ROS production [143]. Experimental 
evidence suggests that the indoleamine hormone melatonin is capable of influencing in 
development of diabetic complications by neutralizing the unnecessary ROS generation and 
protection of beta cells, as they possess low antioxidant potential and normalize redox state 
in the cell [144]. Melatonin acts as a cell survival agent by modulating autophagy in various 
cell types and under different conditions through amelioration of oxidative stress, ER stress, 
and inflammation [143].
7. Conclusion
Melatonin is a circulating neurohormone secreted predominantly at night, thereby called as 
hormone of darkness. It can cross all physiological barriers to exert widespread regulatory 
effects on body tissues. Melatonin is a universal antioxidant with multifunctional activities 
such as anti-inflammatory, antiapoptotic, and antioxidant effects in addition to its function as 
a synchronizer of the biological clock and seasonal reproduction. Melatonin and its deriva-
tives have been shown to be powerful direct free radical scavengers. Besides direct scaveng-
ing of ROS/RNS, melatonin also stimulates antioxidant enzymes; suppresses prooxidant 
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enzymes; improves mitochondrial function, hence reducing radical formation; and reduces 
metal-induced toxicity. Results from previous studies support these effects on several diseases 
including cancer, diabetes, neurodegenerative, cardiovascular, liver; and kidney diseases.
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